A prospective study investigating effect of polymorphisms in CYP2D6, ABCB1, and ABCG2 and the side effects induced by gefitinib on pharmacokinetics of of O-desmethyl gefitinib in japanese subjects with advanced non-small cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- 01 Mar 2017 New trial record